FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2971488669> ?p ?o ?g. }

• W2971488669 endingPage "233" @default.
• W2971488669 startingPage "225" @default.
• W2971488669 abstract "Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case-control study Laith N AL-Eitan1,2, Islam M Al-Dalalah1, Mohamed M Mustafa3, Mansour A Alghamdi4, Afrah K Elshammari5, Wael H Khreisat5, Mohammed N Al-Quasmi6, Hanan A Aljamal1 1Department of Applied Biological Sciences, Jordan University of Science and Technology, Irbid, Jordan; 2Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, Jordan; 3Department of Neuroscience, Jordan University of Science and Technology, Irbid, Jordan; 4Anatomy Department, College of Medicine, King Khalid University, Abha, Saudi Arabia; 5Department of Pediatric Neurology, Queen Rania Hospital for Children, King Hussein Medical Center, Royal Medical Services, Amman, Jordan; 6Department of Medical Laboratory, King Abdullah University Hospital, Irbid, JordanCorrespondence: Laith N AL-EitanJordan University of Science and Technology, P.O. Box 3030, Irbid 22110, JordanTel +962 2 720 1000 Ext.:23464Fax +962 2 720 1071Email lneitan@just.edu.joBackground: A total of 50 million persons were diagnosed worldwide with epilepsy. One-third of them are experiencing debilitating seizures despite optimum anti‐epileptic drugs (AEDs) treatment. Several studies have suggested that CYP3A5, CHRM2, and ZNF498 influence the pharmacokinetics of AEDs. Therefore, the severity of the disease as well as the degree of response to the AEDs could be affected by the genetic polymorphisms within these genes.Objectives: In this study, we assessed the effect of certain single nucleotide polymorphisms (SNPs) within CYP3A5, CHRM2, and ZNF498 genes on the susceptibility to develop epilepsy and the responsiveness to AEDs treatment.Methods: A case–control and pharmacogenetic study was conducted on samples of 299 healthy individuals in addition to 296 epileptic patients. Genotypic, allelic, and clinical data association were performed for the selected polymorphisms within the (rs324649, rs420817, rs15524, and rs1859690) in the Jordanian population.Results: The analysis revealed no significant association of the investigated SNPs with epilepsy in general, partial and generalized epilepsy as well as drug responsiveness. CYP3A5 and ZNF498 were associated with family history (P=0.003 and P=0.002, respectively) and the classification of epilepsy for the ZNF498 variant (P=0.009). On the other hand, CHRM2 was not linked to either disease severity or treatment responsiveness.Conclusion: Our results failed to confirm the association of CYP3A5, ZNF498, and CHRM2 variants with either disease development or treatment response. Clinical pharmacogenetic studies may contribute to treatment personalization, appropriate drug dose selection, minimizing drug adverse reactions, increasing drug efficacy, and reducing the costive burdens.Keywords: epilepsy, seizures, cytochrome P-450 CYP3A, pharmacogenetics, humans, anti-epileptic drugs" @default.
• W2971488669 created "2019-09-12" @default.
• W2971488669 creator A5025058824 @default.
• W2971488669 creator A5029710473 @default.
• W2971488669 creator A5045115397 @default.
• W2971488669 creator A5056451010 @default.
• W2971488669 creator A5069336080 @default.
• W2971488669 creator A5075668737 @default.
• W2971488669 creator A5079453950 @default.
• W2971488669 creator A5085557672 @default.
• W2971488669 date "2019-09-01" @default.
• W2971488669 modified "2023-09-27" @default.
• W2971488669 title "<p>Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case–control study</p>" @default.
• W2971488669 cites W1482994761 @default.
• W2971488669 cites W1962920773 @default.
• W2971488669 cites W1965935955 @default.
• W2971488669 cites W1968738343 @default.
• W2971488669 cites W1986975701 @default.
• W2971488669 cites W1997923319 @default.
• W2971488669 cites W2016907728 @default.
• W2971488669 cites W2023430975 @default.
• W2971488669 cites W2041057539 @default.
• W2971488669 cites W2051422870 @default.
• W2971488669 cites W2057558890 @default.
• W2971488669 cites W2060555831 @default.
• W2971488669 cites W2081281742 @default.
• W2971488669 cites W2099169745 @default.
• W2971488669 cites W2106771632 @default.
• W2971488669 cites W2107755054 @default.
• W2971488669 cites W2120475330 @default.
• W2971488669 cites W2160939326 @default.
• W2971488669 cites W2195214386 @default.
• W2971488669 cites W2206010939 @default.
• W2971488669 cites W2301815399 @default.
• W2971488669 cites W2330866171 @default.
• W2971488669 cites W2408962255 @default.
• W2971488669 cites W2560344182 @default.
• W2971488669 cites W2569621292 @default.
• W2971488669 cites W2574799308 @default.
• W2971488669 cites W2610383469 @default.
• W2971488669 cites W2796687870 @default.
• W2971488669 cites W2802849710 @default.
• W2971488669 cites W2900723135 @default.
• W2971488669 cites W2948295112 @default.
• W2971488669 cites W3023267826 @default.
• W2971488669 doi "https://doi.org/10.2147/pgpm.s212433" @default.
• W2971488669 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6732506" @default.
• W2971488669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31564953" @default.
• W2971488669 hasPublicationYear "2019" @default.
• W2971488669 type Work @default.
• W2971488669 sameAs 2971488669 @default.
• W2971488669 citedByCount "3" @default.
• W2971488669 countsByYear W29714886692020 @default.
• W2971488669 countsByYear W29714886692022 @default.
• W2971488669 countsByYear W29714886692023 @default.
• W2971488669 crossrefType "journal-article" @default.
• W2971488669 hasAuthorship W2971488669A5025058824 @default.
• W2971488669 hasAuthorship W2971488669A5029710473 @default.
• W2971488669 hasAuthorship W2971488669A5045115397 @default.
• W2971488669 hasAuthorship W2971488669A5056451010 @default.
• W2971488669 hasAuthorship W2971488669A5069336080 @default.
• W2971488669 hasAuthorship W2971488669A5075668737 @default.
• W2971488669 hasAuthorship W2971488669A5079453950 @default.
• W2971488669 hasAuthorship W2971488669A5085557672 @default.
• W2971488669 hasBestOaLocation W29714886691 @default.
• W2971488669 hasConcept C104317684 @default.
• W2971488669 hasConcept C118552586 @default.
• W2971488669 hasConcept C126322002 @default.
• W2971488669 hasConcept C135763542 @default.
• W2971488669 hasConcept C153209595 @default.
• W2971488669 hasConcept C2778186239 @default.
• W2971488669 hasConcept C3017595490 @default.
• W2971488669 hasConcept C54355233 @default.
• W2971488669 hasConcept C55775858 @default.
• W2971488669 hasConcept C71924100 @default.
• W2971488669 hasConcept C86803240 @default.
• W2971488669 hasConceptScore W2971488669C104317684 @default.
• W2971488669 hasConceptScore W2971488669C118552586 @default.
• W2971488669 hasConceptScore W2971488669C126322002 @default.
• W2971488669 hasConceptScore W2971488669C135763542 @default.
• W2971488669 hasConceptScore W2971488669C153209595 @default.
• W2971488669 hasConceptScore W2971488669C2778186239 @default.
• W2971488669 hasConceptScore W2971488669C3017595490 @default.
• W2971488669 hasConceptScore W2971488669C54355233 @default.
• W2971488669 hasConceptScore W2971488669C55775858 @default.
• W2971488669 hasConceptScore W2971488669C71924100 @default.
• W2971488669 hasConceptScore W2971488669C86803240 @default.
• W2971488669 hasLocation W29714886691 @default.
• W2971488669 hasLocation W29714886692 @default.
• W2971488669 hasLocation W29714886693 @default.
• W2971488669 hasLocation W29714886694 @default.
• W2971488669 hasOpenAccess W2971488669 @default.
• W2971488669 hasPrimaryLocation W29714886691 @default.
• W2971488669 hasRelatedWork W2027336288 @default.
• W2971488669 hasRelatedWork W2107074164 @default.
• W2971488669 hasRelatedWork W2124249410 @default.
• W2971488669 hasRelatedWork W2276916552 @default.
• W2971488669 hasRelatedWork W2283861756 @default.

• next